Hot Flashes Treatment Pipeline Expands with 15+ Novel Therapies from Leading Pharmaceutical Companies
Key Insights
DelveInsight's 2025 pipeline report identifies over 15 companies developing innovative therapies for hot flashes (search), including first-in-class neurokinin receptor antagonists and novel estrogen receptor (search) modulators.
Bayer's elinzanetant and Astellas Pharma's fezolinetant represent promising dual and selective neurokinin receptor antagonists targeting vasomotor symptoms (search) through hypothalamic KNDy neuron modulation.
Veru Inc's zuclomiphene citrate demonstrated statistically significant reduction in moderate to severe hot flashes (search) in men with advanced prostate cancer (search) receiving androgen deprivation therapy.
The hot flashes (search) treatment landscape is experiencing unprecedented innovation, with over 15 pharmaceutical companies advancing novel therapeutic approaches to address this debilitating condition affecting millions of patients worldwide. According to DelveInsight's comprehensive 2025 pipeline analysis, the field encompasses more than 15 pipeline drugs spanning from early discovery through late-stage clinical development.
Neurokinin Receptor Antagonists Lead Innovation
The most promising developments center on neurokinin receptor antagonists, representing a paradigm shift toward non-hormonal treatment options. Bayer's elinzanetant stands out as a first-in-class, dual neurokinin-1,3 receptor (search) antagonist currently in clinical development for vasomotor symptoms (search) during menopause (search). The compound addresses hot flashes (search) by modulating estrogen-sensitive neurons in the hypothalamus known as KNDy neurons (search), which become hyperactive in menopausal women due to estrogen absence, disrupting body heat control mechanisms.
On October 29, 2025, Bayer initiated a study to evaluate elinzanetant's efficacy in treating hot flashes (search) caused by anti-cancer therapy in women with or at high risk for developing HR-positive breast cancer (search) compared to placebo.
Astellas Pharma's fezolinetant represents another breakthrough as an investigational selective neurokinin-3 (NK3) receptor antagonist. If approved by regulatory authorities, fezolinetant would become a first-in-class, nonhormonal treatment option to reduce the frequency and severity of vasomotor symptoms (search) associated with menopause (search). On October 28, 2025, Astellas announced a confirmatory study in Japanese women going through menopause, utilizing electronic handheld devices with apps to track hot flash episodes.
Diverse Therapeutic Mechanisms Under Investigation
Ogeda (search)'s proprietary version of fezolinetant (ESN364) demonstrates the compound's versatility beyond menopause (search) treatment. The oral small-molecule therapy mimics estrogen's neuronal effects to control body temperature while addressing multiple women's health disorders. The drug selectively lowers luteinizing hormone without affecting follicle-stimulating hormone, potentially restoring menstrual cycle regularity and fertility in PCOS (search) patients.
Veru Inc's zuclomiphene citrate has shown particularly promising results in an underserved patient population. The novel, proprietary, oral, nonsteroidal estrogen receptor (search) agonist demonstrated statistically significant reduction in the frequency of moderate to severe hot flashes (search) in men with advanced prostate cancer (search) receiving androgen deprivation therapy (ADT) in a Phase 2 clinical trial.
Comprehensive Pipeline Development
The hot flashes (search) pipeline encompasses diverse molecular approaches including small molecules, thiadiazoles, and recombinant proteins. Leading companies such as Veru Healthcare, Fervent Pharmaceuticals, Ogeda (search), Bayer, Lundbeck A/S (search), TherapeuticsMD, MenoGeniX (search), Mitsubishi Tanabe Pharma (search), QUE Oncology, and Pherin Pharmaceuticals are actively developing therapies across multiple administration routes including oral, intravenous, and subcutaneous delivery systems.
The therapeutic landscape includes established compounds being repurposed for hot flash treatment, such as gabapentin and tamoxifen, alongside novel investigational agents like NK3R antagonist-AZD4901 (search), FP-101, MF101, and RAD1901.
Clinical Development Spans All Phases
Current pipeline development encompasses the full spectrum of clinical stages, from discovery and preclinical research through Phase III trials. Zuclomiphene citrate from Veru Inc represents one of the most advanced programs in late-stage development, while mid-stage products include Eiger BioPharmaceuticals (search)' avexitide and Lundbeck A/S (search)'s SJX 653.
The robust pipeline reflects growing recognition of hot flashes (search) as a significant medical condition requiring targeted therapeutic intervention. Hot flashes represent a rapid and exaggerated heat dissipation response consisting of profuse sweating, peripheral vasodilation, and feelings of intense internal heat, triggered by small elevations in core body temperature within a greatly reduced thermoneutral zone.
This expanding therapeutic landscape addresses critical unmet medical needs across diverse patient populations, from menopausal women to cancer patients experiencing treatment-induced vasomotor symptoms (search), potentially transforming treatment paradigms for this prevalent and impactful condition.